Literature DB >> 1543669

Disease associations and pathogenic role of antineutrophil cytoplasmic autoantibodies in vasculitis.

J C Jennette1, R J Falk.   

Abstract

Antineutrophil cytoplasmic autoantibodies are a useful diagnostic serologic marker for a variety of well-known vasculitic syndromes, including Wegener's granulomatosis, polyarteritis nodosa (especially microscopic polyarteritis nodosa), Churg-Strauss syndrome, and pulmonary-renal syndrome with alveolar capillaritis. Although most patients with antineutrophil cytoplasmic autoantibody-associated disease have systemic disease, disease limited to one organ does occur, eg, isolated necrotizing glomerulonephritis, isolated respiratory tract disease, or isolated orbital disease. Antineutrophil cytoplasmic autoantibody titers may be useful in modulating treatment regimens. There is in vitro evidence that antineutrophil cytoplasmic autoantibodies are directly involved in the pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitides.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1543669

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  4 in total

1.  Anti-neutrophil cytoplasmic antibody in patients with systemic lupus erythematosus is unrelated to clinical features.

Authors:  K Nishiya; H Chikazawa; S Nishimura; N Hisakawa; K Hashimoto
Journal:  Clin Rheumatol       Date:  1997-01       Impact factor: 2.980

2.  Relapsing Wegener's granulomatosis: successful treatment with cyclosporin-A.

Authors:  C Georganas; D Ioakimidis; C Iatrou; B Vidalaki; K Iliadou; P Athanassiou; T Kontomerkos
Journal:  Clin Rheumatol       Date:  1996-03       Impact factor: 2.980

Review 3.  The clinical relevance of ANCA in vasculitis.

Authors:  W L Gross; S Hauschild; N Mistry
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

Review 4.  Laboratory testing in the evaluation and diagnosis of vasculitis.

Authors:  M L Cuellar; L R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2000-10       Impact factor: 4.686

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.